

Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

**Investigator, The Lundquist Institute
Professor of Psychiatry & Biobehavioral Sciences and Pediatrics, David Geffen School of
Medicine at UCLA**

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2021) - Lobe Sciences Ltd. ("**Lobe**" or the "**Company**") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce the appointment of Charles Grob, MD Investigator, The Lundquist Institute, and Professor of Psychiatry & Biobehavioral Sciences and Pediatrics, David Geffen School of Medicine at UCLA, to its Advisory Board.

Philip Young, CEO and Director of Lobe stated, "We are honored to welcome Charles to our Scientific Advisory Board with his extensive background. Dr. Grob will add tremendous value to the team as we move forward with implementing our drug development platform."

Charles S. Grob, M.D. is Professor of Psychiatry and Pediatrics at the UCLA School of Medicine. He previously held faculty positions at the Johns Hopkins School of Medicine and the University of California at Irvine. He has conducted approved clinical research with psychedelics since the early 1990s. From 2004-2008 he was the Principal Investigator of the first study in several decades to examine the use of a psilocybin treatment model for patients with advanced-cancer anxiety. He has also conducted research into the range of effects of MDMA, in both normal volunteers and in a selected subject population of adult autistics with severe social anxiety. And, he has conducted a series of ayahuasca research studies in Brazil. Over the last thirty years, Dr. Grob has published numerous articles on psychedelics in the medical and psychiatric literatures and he is the editor of *Hallucinogens: A Reader* (Putnam/Tarcher, 2002), co-editor (with Roger Walsh) of *Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics* (SUNY Press, 2005) and co-editor (with James Grigsby) of the recently published *Handbook of Medical Hallucinogens* (Guilford Press, 2021). He is a founding board member of the Heffter Research Institute.

Charles Grob, MD. stated, "I am pleased to join the established members of Lobe's Advisory Board and look forward to the opportunity to assist the team in bringing psychedelic medicine in to clinical practice."

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.

Philip J Young, CEO

info@lobesciences.com

Tel: (949) 505-5623

*THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE
ACCURACY OR ADEQUACY OF THIS RELEASE.*

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often

identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, progression with nasal mist device engineering and commercialization, the pursuit of M&A initiatives, development of effective delivery methods and commercialization potential of the nasal mist device, research and development using NAC and psilocybin and growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.



LOBE
SCIENCES

To view the source version of this press release, please visit
<https://www.newsfilecorp.com/release/88841>